Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 27, 2026, 5:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Thoracic Tumors Clear all
Completed Not applicable Interventional

Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family Caregivers

NCT02243748
View directory record Official record
Conditions
Caregiver, Psychological Impact of Cancer and Its Treatment, Recurrent Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
Palliative Therapy, quality-of-life assessment, questionnaire administration
Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
5
States / cities
Duarte, California • Irvine, California • Ontario, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Jun 27, 2026, 5:26 AM EDT
Completed No phase listed Observational

Concordance of Inivata Liquid Biopsy With Standard of Care Tissue Testing

NCT02906852
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Not listed
Lead sponsor
Inivata
Industry
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
35
States / cities
Mission Hills, California • Aurora, Colorado • Norwich, Connecticut + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Jun 27, 2026, 5:26 AM EDT
Terminated No phase listed Observational

Observational Study of Best Supportive Care With or Without Surgery, Chemo or Radiotherapy in Pts With Carcinoma of Lung

NCT00822016
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 28, 2012 · Synced Jun 27, 2026, 5:26 AM EDT
Recruiting Not applicable Interventional

New York Better Breathing Study

NCT06869447
View directory record Official record
Conditions
Localized Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8
Interventions
Biospecimen Collection, Electronic Health Record Review, Medical Device Usage and Evaluation, Questionnaire Administration, Respiratory Muscle Training, Sham Intervention
Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jun 27, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

Vinorelbine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

NCT00008333
View directory record Official record
Conditions
Lung Cancer
Interventions
vinorelbine tartrate
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
13
States / cities
Scottsdale, Arizona • Urbana, Illinois • Cedar Rapids, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Jun 27, 2026, 5:26 AM EDT
Active, not recruiting Not applicable Interventional

Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer

NCT04751747
View directory record Official record
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Small Cell Carcinoma
Interventions
Computed Tomography, Contrast Agent
Procedure · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jun 27, 2026, 5:26 AM EDT
Terminated Phase 2 Interventional

Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients

NCT01832857
View directory record Official record
Conditions
Cancer
Interventions
CPI-613
Drug
Lead sponsor
Cornerstone Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Jun 27, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer

NCT00004065
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Head and Neck Cancer, Kidney Cancer, Leukemia, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
tanespimycin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2013 · Synced Jun 27, 2026, 5:26 AM EDT
Active, not recruiting Not applicable Interventional

Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules

NCT06638398
View directory record Official record
Conditions
Lung Neoplasm
Interventions
Computed Tomography, Diagnostic Procedure, Best Practice, Electronic Health Record Review
Procedure · Device · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
35 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
5
States / cities
Aurora, Colorado • St Louis, Missouri • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 27, 2026, 5:26 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

NCT02838836
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer, Hepatocellular Cancer, Colorectal Cancer
Interventions
Study sample collection
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
620 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Jun 27, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease

NCT00084409
View directory record Official record
Conditions
Lung Cancer, Precancerous Condition
Interventions
iloprost, placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
6
States / cities
Aurora, Colorado • Denver, Colorado • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Jun 27, 2026, 5:26 AM EDT
Completed Phase 1Phase 2 Interventional

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

NCT00397293
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
AT-101, topotecan
Drug
Lead sponsor
Ascenta Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Loma Linda, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Jun 27, 2026, 5:26 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Ponatinib for Squamous Cell Lung and Head and Neck Cancers

NCT01761747
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Head and Neck Cancer
Interventions
ponatinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Jun 27, 2026, 5:26 AM EDT
Completed Phase 2 Interventional

S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

NCT00030433
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
102
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Jun 27, 2026, 5:26 AM EDT
Withdrawn Phase 2 Interventional

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

NCT05161533
View directory record Official record
Conditions
Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Carboplatin, Cisplatin, Durvalumab, Etoposide, Hypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 17, 2023 · Synced Jun 27, 2026, 5:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Calcitriol in Lung Cancer

NCT00794547
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Calcitriol
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
4
States / cities
Ann Arbor, Michigan • Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Jun 27, 2026, 5:26 AM EDT
Terminated Phase 2 Interventional

Oxaliplatin/CPT-11 for Extensive Stage Small Cell Lung Cancer

NCT00316433
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Irinotecan (CPT-11), Oxaliplatin (Eloxatin)
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 4, 2007 · Synced Jun 27, 2026, 5:26 AM EDT
Suspended Phase 1 Interventional

The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint Inhibitors

NCT05967533
View directory record Official record
Conditions
Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Renal Cell Carcinoma, Advanced Triple-Negative Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer (AJCC) v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Renal Cell Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Fermented Wheat Germ Extract
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jun 27, 2026, 5:26 AM EDT
Terminated Phase 3 Interventional

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00551733
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, paclitaxel poliglumex
Drug
Lead sponsor
CTI BioPharma
Industry
Eligibility
18 Years to 120 Years · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
41
States / cities
Scottsdale, Arizona • Burbank, California • Escondido, California + 36 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2020 · Synced Jun 27, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer

NCT02000947
View directory record Official record
Conditions
NSCLC, Non-small Cell Lung Cancer, Lung Cancer
Interventions
MEDI4736, tremelimumab
Drug
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 101 Years
Enrollment
459 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
28
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Jun 27, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

A Study for Participants With Small-Cell Lung Cancer

NCT01025284
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
LY2523355, Granulocyte colony-stimulating factor (G-CSF)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Torrington, Connecticut • Athens, Georgia • Marietta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Jun 27, 2026, 5:26 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

NCT03095352
View directory record Official record
Conditions
Breast Cancer, Chest Wall Disease
Interventions
Pembrolizumab, Carboplatin, Trastuzumab
Biological · Drug
Lead sponsor
Laura Huppert, MD, BA
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Jun 27, 2026, 5:26 AM EDT
Completed Phase 1 Interventional

Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

NCT00104767
View directory record Official record
Conditions
Lung Cancer
Interventions
celecoxib
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2015 · Synced Jun 27, 2026, 5:26 AM EDT
Terminated Phase 2 Interventional

Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer

NCT00420732
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
HyperAcute-Lung Cancer Vaccine
Biological
Lead sponsor
NewLink Genetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Jun 27, 2026, 5:26 AM EDT